BR112012014060A2 - métodos e reagentes para detecção aprimorada de peptídeos beta-amiloides - Google Patents

métodos e reagentes para detecção aprimorada de peptídeos beta-amiloides

Info

Publication number
BR112012014060A2
BR112012014060A2 BR112012014060A BR112012014060A BR112012014060A2 BR 112012014060 A2 BR112012014060 A2 BR 112012014060A2 BR 112012014060 A BR112012014060 A BR 112012014060A BR 112012014060 A BR112012014060 A BR 112012014060A BR 112012014060 A2 BR112012014060 A2 BR 112012014060A2
Authority
BR
Brazil
Prior art keywords
beta
methods
neurodegenerative disease
reagents
amyloid peptides
Prior art date
Application number
BR112012014060A
Other languages
English (en)
Other versions
BR112012014060B1 (pt
BR112012014060B8 (pt
Inventor
José Manuel Sarasa Barrio
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Publication of BR112012014060A2 publication Critical patent/BR112012014060A2/pt
Publication of BR112012014060B1 publication Critical patent/BR112012014060B1/pt
Publication of BR112012014060B8 publication Critical patent/BR112012014060B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

métodos e reagentes para detecção aprimorada de peptídeos beta-amiloides. a presente invenção refere-se a métodos para o diagnóstico de uma doença neurodegenerativa, para a detecção de um estágio anterior a uma doença neurodegenerativa ou para diferenciar doença neurodegenerativa de um estágio anterior a um doença neurodegenerativa com base no nível de determinados conjuntos de peptídeos beta-amiloides os quais são quer ligados a componentes plasméticos ou ligados a células sanguíneas bem como em determinados parâmetros calculados os quais são obtidos por uma combinação aritmética dos níveis de um ou mais dos peptídeos amiloides. a invenção se refere também a kits para realização do método acima.
BR112012014060A 2009-12-11 2010-12-13 método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda BR112012014060B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382279.9 2009-12-11
EP09382279 2009-12-11
PCT/EP2010/069474 WO2011070174A1 (en) 2009-12-11 2010-12-13 Methods and reagents for improved detection of amyloid beta peptides

Publications (3)

Publication Number Publication Date
BR112012014060A2 true BR112012014060A2 (pt) 2016-12-13
BR112012014060B1 BR112012014060B1 (pt) 2021-01-19
BR112012014060B8 BR112012014060B8 (pt) 2021-07-27

Family

ID=41818879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014060A BR112012014060B8 (pt) 2009-12-11 2010-12-13 método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda

Country Status (21)

Country Link
US (2) US20120264642A1 (pt)
EP (1) EP2510359B1 (pt)
JP (1) JP5745531B2 (pt)
KR (1) KR101531949B1 (pt)
CN (1) CN102713633B (pt)
AR (1) AR079443A1 (pt)
AU (1) AU2010329844B2 (pt)
BR (1) BR112012014060B8 (pt)
CA (1) CA2782250C (pt)
DK (1) DK2510359T3 (pt)
ES (1) ES2552627T3 (pt)
HK (1) HK1175242A1 (pt)
HU (1) HUE028105T2 (pt)
IL (1) IL220276A (pt)
IN (1) IN2012DN05056A (pt)
MX (1) MX2012006512A (pt)
PL (1) PL2510359T3 (pt)
PT (1) PT2510359E (pt)
RU (1) RU2554774C2 (pt)
TW (1) TWI509246B (pt)
WO (1) WO2011070174A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140128230A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트
EP3147668B1 (en) * 2014-05-22 2019-12-11 Shimadzu Corporation Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
AU2015311836B2 (en) * 2014-09-05 2021-03-11 Presympto, Inc. Methods for detecting amyloid beta oligomers
KR101786859B1 (ko) * 2015-04-30 2017-10-17 서울대학교산학협력단 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법
RU2611408C1 (ru) * 2015-09-23 2017-02-21 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Чувашский государственный университет имени И.Н. Ульянова" Способ флуоресцентного гистологического выявления амилоида
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
EP3760640A4 (en) * 2018-02-27 2021-11-17 Shimadzu Corporation ANTIBODIES SPECIFICALLY RECOGNIZING THE N-TERMINAL END OF APP669-X, AND METHOD OF IMMUNOLOGICAL ASSAY
WO2019167128A1 (ja) * 2018-02-27 2019-09-06 株式会社 島津製作所 サンドイッチ型免疫測定法
RU2708465C1 (ru) * 2019-02-18 2019-12-09 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ детекции модификаций амилоидного пептида с помощью высокоспецифичных антител
CN113597429A (zh) * 2019-03-01 2021-11-02 株式会社岛津制作所 App669-711测定方法及测定用试剂盒
GB201904810D0 (en) 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
BR112021022421A2 (pt) * 2019-05-10 2021-12-28 Quest Diagnostics Invest Llc Ensaio multiplex para determinar a razão de ss-amiloide 42/40 em espécimes de plasma humano
WO2021009074A1 (en) 2019-07-12 2021-01-21 Adx Neurosciences Nv Novel markers as early predictors of alzheimer's pathology
CN116574271B (zh) * 2023-06-06 2023-12-19 苏州谱迪生物科技有限公司 一种用于免疫检测低丰度生物标志物信号级联放大的荧光树状大分子的制备方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976817A (en) * 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
EP3070100B1 (en) 2000-02-24 2021-07-07 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP4511830B2 (ja) 2001-08-17 2010-07-28 ワシントン・ユニバーシティ アルツハイマー病のアッセイ方法
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
US20040096907A1 (en) * 2002-11-06 2004-05-20 Bernd Bohrmann Quantification of beta amyloid
ES2246178B1 (es) 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
US20070003977A1 (en) * 2003-08-20 2007-01-04 Amorfix Life Sciences Ltd Epitope protection assay and method for detecting protein conformations
US20080199879A1 (en) 2004-10-28 2008-08-21 Sanko Junyaku Co., Ltd. Method of Assaying Alzheimer's Disease and Diagnostic Reagent
EP1820019A4 (en) 2004-11-12 2008-05-14 Pfizer METHOD FOR MEASURING BETA-AMYLOID PEPTIDES
WO2007022015A1 (en) 2005-08-12 2007-02-22 Georgetown University Methods to evaluate amyloid beta-lowering agents using wild-type mice
EP1940466B1 (en) 2005-10-21 2012-11-28 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibodies and use thereof
EP2020602A1 (en) 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
WO2009048631A1 (en) * 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
WO2011064225A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment

Also Published As

Publication number Publication date
WO2011070174A1 (en) 2011-06-16
PL2510359T3 (pl) 2016-02-29
AR079443A1 (es) 2012-01-25
CN102713633A (zh) 2012-10-03
US20210011032A1 (en) 2021-01-14
HUE028105T2 (en) 2016-11-28
BR112012014060B1 (pt) 2021-01-19
RU2554774C2 (ru) 2015-06-27
PT2510359E (pt) 2015-12-02
EP2510359B1 (en) 2015-09-02
TWI509246B (zh) 2015-11-21
TW201131167A (en) 2011-09-16
ES2552627T3 (es) 2015-12-01
CN102713633B (zh) 2015-03-11
DK2510359T3 (en) 2015-12-07
IL220276A0 (en) 2012-07-31
IN2012DN05056A (pt) 2015-10-09
US20120264642A1 (en) 2012-10-18
JP5745531B2 (ja) 2015-07-08
CA2782250C (en) 2016-08-30
HK1175242A1 (en) 2013-06-28
IL220276A (en) 2016-02-29
AU2010329844A1 (en) 2012-06-14
JP2013513791A (ja) 2013-04-22
BR112012014060B8 (pt) 2021-07-27
KR20120115306A (ko) 2012-10-17
MX2012006512A (es) 2012-08-17
AU2010329844B2 (en) 2015-07-16
CA2782250A1 (en) 2011-06-16
EP2510359A1 (en) 2012-10-17
KR101531949B1 (ko) 2015-06-26
RU2012129184A (ru) 2014-01-20

Similar Documents

Publication Publication Date Title
BR112012014060A2 (pt) métodos e reagentes para detecção aprimorada de peptídeos beta-amiloides
CY1123172T1 (el) Δοκιμασια για συλληψη και ανιχνευση κυκλοφορουντων κυτταρων πολλαπλου μυελωματος απο αιμα
MX341840B (es) Biomarcadores de microarn indicativos de la enfermedad de alzheimer.
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
EA201391587A1 (ru) Комбинированная терапия на основе hsp90
WO2015006705A3 (en) Micrornas that silence tau expression
NO20083957L (no) DNA-konformasjon
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
BR112014019168A2 (pt) ensaio capaz de detectar de forma não degenerada presença ou ausência de analitos em um único volume de amostra, bem como método de detecção da presença ou ausência de analito dentre uma pluralidade dos mesmos
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
BR112013004673A8 (pt) biomarcadores e métodos de tratamento.
BRPI0715408B8 (pt) Processo para a preparação de 5-(1-alquiltio)alquilpiridinas 2-substituída
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
WO2013181418A3 (en) Multiplexed diagnosis method for classical hodgkin lymphoma
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
BR112018008749A8 (pt) métodos de detecção de apolipoproteína
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
BRPI0606619A2 (pt) método de análise de oligossacarìdeos, a partir do plasma sangüìneo
WO2013090857A8 (en) Identification of two novel biomarkers for niemann-pick disease type c
AU2012313353A8 (en) Screening method
EA201590495A1 (ru) Способ диагностики и лечения рака, направленный на молекулы, экспрессируемые в раковых стволовых клетках
BR112015013498A2 (pt) método para o diagnóstico de leucodistrofia metacromática
BR112015010276A2 (pt) peptídeos miméticos
FR2963791B1 (fr) Methode de diagnostic des maladies neurodegeneratives
PT2807486T (pt) Método para a previsão in vitro, numa amostra sanguínea, da probabilidade de um paciente desenvolver dengue grave

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: ARACLON BIOTECH, S.L (ES)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/12/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO